In a randomized trial of high-dose EPO (total dose of 100,000 IU over 3 consecutive days) in donation after cardiac death (DCD) kidney transplant patients, EPO treatment significantly increased the risk of thromboembolic events at 1 month (17.8% vs 4.3%, P = 0.048) and 1 year (24.4% vs 6.4%, P = 0.020). The gene discussed is EPO; the disease is kidney transplant.